Evidence map›Paper›PMID 42181661›Full record

ArticleJID innovations : skin science from molecules to population health2026

Lymphangiogenesis in hypercholesterolemic skin: A comparative study of xanthomatous and non-xanthomatous lesions.

Enkhtuul Gantumur, Nao Itai, Kazuki Takagaki, Nobuyuki Mitsukawa, Shinsuke Akita, Kentaro Kajiya

Abstract read
In one paragraph

Article in JID innovations : skin science from molecules to population health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Enkhtuul GantumurMIRAI Technology Institute, Shiseido Co., Ltd., Yokohama, Japan.
Nao ItaiMIRAI Technology Institute, Shiseido Co., Ltd., Yokohama, Japan.
Kazuki TakagakiMIRAI Technology Institute, Shiseido Co., Ltd., Yokohama, Japan.
Nobuyuki MitsukawaDepartment of Plastic, Reconstructive, and Aesthetic Surgery, Chiba University, Japan.
Shinsuke AkitaDepartment of Plastic, Reconstructive, and Aesthetic Surgery, Chiba University, Japan.
Kentaro KajiyaMIRAI Technology Institute, Shiseido Co., Ltd., Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While hypercholesterolemia is the primary driver of atherosclerosis, emerging evidence indicates that lymphatic vessels are critical for cholesterol transport and become impaired under hyperlipidemic conditions. Xanthelasma palpebrarum, characterized by cholesterol-laden yellowish plaques on the eyelids, is a cutaneous manifestation of dyslipidemia, yet the relationship between local cholesterol accumulation and dermal lymphatic function remains elusive. Here, we compare the lymphatic vessel morphology of xanthomatous and non-xanthomatous skin lesions in patients with various levels of serum low-density lipoprotein cholesterol. Dermal lymphatic vessel abundance was positively correlated with serum low-density lipoprotein cholesterol levels in both lesion types. Elevated low-density lipoprotein cholesterol was associated with upregulated VEGF-C expression in macrophages and increased lymphatic proliferation, indicating aberrant lymphangiogenesis in hypercholesterolemic skin. These findings reveal a previously unrecognized link between systemic cholesterol metabolism and lymphatic remodeling in human skin. The observed lymphangiogenic response may represent a compensatory mechanism for impaired cholesterol clearance or may contribute to the pathogenesis of xanthoma.

Indexed as

Dermal lymphaticsHypercholesterolemiaLDL cholesterolLymphangiogenesisXanthelasma palpebrarum

Identifiers

PMID42181661
PMCPMC13194631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.